Advertisement Pharmaceutical Business review -

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 16, 2019

Roche gets FDA nod for Rozlytrek to treat ROS1-positive NSCLC

Roche has secured approval from the US Food and Drug Administration (FDA) for its Rozlytrek (entrectinib) to treat adults with ROS1-positive and metastatic non-small cell lung cancer (NSCLC).

Image: Site Roche Basel. Photo: courtesy of F. Hoffmann-La Roche Ltd.